

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In Re Application of: See Schedule

Serial No.: See Schedule

Filed: See Schedule

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

REVOCATION AND NEW POWER BY ASSIGNEE AND STATEMENT UNDER 37 C.F.R. §3.73(b)

The Assignee (**Medical College of Georgia Research Institute, Inc.**) of the entire right, title, and interest in the applications listed in the attached Schedule A hereby revokes all previously granted powers and grants the registered practitioners of Cooley Godward Kronish LLP included in the Customer Number provided below power to act, prosecute, and transact all business in the U.S. Patent and Trademark Office in connection with these applications, any applications claiming priority to these applications, and any patents issuing therefrom.

The assignee certifies that to the best of its knowledge and belief it is the owner of the entire right, title, and interest in and to the applications identified in the attached Appendix A as evidenced by:

- ☐ An assignment document, a copy of which is enclosed herewith;
- ☒ An assignment previously recorded in the U.S. Patent and Trademark Office at the Reel/Frame indicated in the attached Schedule.

Please direct all telephone calls and correspondence to:

CUSTOMER NUMBER: **58249**

COOLEY GODWARD KRONISH LLP
ATTN: Patent Group
777 6th Street NW, Suite 1100
Washington, DC 20001
Tel: (202) 842-7800
Fax: (202) 842-7899

The undersigned (whose title is supplied below) is empowered to sign this statement on behalf of the assignee.

Date: 3/16/09

Signature: Betty Aldridge
Name: Betty Aldridge
Title: Executive Director
Company: MCG Research Institute, Inc.
Medical College of Georgia Research
Institute, Inc.
1120 15th Street
Augusta, GA 30912

SCHEDULE A

Docket Number	MCS Number	Country	Serial Number	Title	Filing Date	Reel/frame
NEWL-005/02US 142996-2008	009-03	US	10/780,150	Regulation of T Cell-Mediated Immunity by D Isomers of Inhibitors of Indoleamine-2, 3-Dioxygenase	02/17/2004	014873/0966
NEWL-005/03US 142996-2032	009-03	US	12/175,518	Regulation of T Cell-Mediated Immunity by D Isomers of Inhibitors of Indoleamine-2, 3-Dioxygenase	07/18/2008	014873/0966
NEWL-006/02US 142996-2007	009-03	US	10/780,797	Use of Inhibitors of Indoleamine-2, 3-Dioxygenase in Combination with Other Therapeutic Modalities	02/17/2004	014844/0587
NEWL-006/03US 142996-2033	009-03	US	12/175,538	Use of Inhibitors of Indoleamine-2, 3-Dioxygenase in Combination with Other Therapeutic Modalities	07/18/2008	014844/0587